Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

Asia Pacific Family Medicine

Open Access

Varicella encephalitis and pneumonia in a patient with end stage renal failure

  • Lian Leng Low1Email author,
  • Farhad Fakhrudin Vasanwala1 and
  • Sufi Muhammad Suhail2
Asia Pacific Family Medicine201413:4

https://doi.org/10.1186/1447-056X-13-4

Received: 18 June 2013

Accepted: 17 February 2014

Published: 21 February 2014

Abstract

We describe a patient with end stage renal failure (ESRF) on hemodialysis who was admitted to our department for primary varicella infection complicated by varicella pneumonia and encephalitis. Varicella infections results in serious morbidity and mortality in ESRF dialysis and transplant patients. Evidence published thus far suggests that live attenuated varicella vaccines are effective and safe in ESRF and renal transplant patients. Worldwide a few countries have instituted guidelines for the varicella immunisation in ESRF patients. However, in the Asia Pacific Region, it has not been widely given due to the lack of national consensus guidelines. Our case depicts that primary varicella infection can occur at any time in immunosupressed patients and thus suffer serious consequences from it. With increasing burden of chronic kidney disease, Renal Physicians and Family Physicians in the Asia Pacific Region should meet and study the epidemiological data in each individual country and decide on the consensus guidelines on how the varicella vaccination can be targeted for those at risk.

Keywords

End stage renal failureVaricellaVaccination

Background

Our case report illustrates the serious complications of varicella in a patient with end stage renal failure and emphasizes the need for consensus guidelines on varicella vaccinations in such patients in the Asia Pacific region. Although evidence in literature show that live attenuated vaccines can be safe & effective, these vaccines are still generally avoided due to lack of consensus guidelines on vaccinations in patients with end stage renal failure. Literature review provides evidence on the safety and efficacy of varicella vaccination in end stage renal failure patients. With the increasing burden of chronic kidney disease, family physicians also need to be alert for these complications of varicella and can play a big role in facilitating varicella vaccination in patients with end stage renal failure.

Case presentation

Our patient is a 58 year old construction supervisor with background of hypertension and ESRF on haemodialysis three times per week. He was admittted via the Accident and Emergency Department to Singapore General Hospital Department of Family Medicine and Continuing Care for fever, chills and non productive cough of two days duration. There was no travel or contact history. On examination, he was alert, non-toxic looking and orientated to time, place and person. He had a temperature of 38.4 degree Celsius, blood pressure of 140/90 mmHg, pulse rate of 80 per minute and respiratory rate of 16 per minute. His respiratory examination revealed reduced chest expansion over the left lung base associated with dullness to percussion, bronchial breath sounds and crackles. His cardiovascular, abdominal and neurological examination was unremarkable. A chest radiograph confirmed consolidation in the left lower zone with milder air space opacity in the right lower zone. He was initially diagnosed with healthcare associated pneumonia in view of recent hospitalization and started on intravenous tazocin. Respiratory viruses multiplex PCR (Polymerase Chain Reaction) was negative.

On the fourth day of admission, he developed vesiculo-papular pruritic lesions mainly over the trunk. Varicella Zoster Virus (VZV) IgM was positive. He was isolated together with air-borne and contact precautions, and started on oral Valacyclovir 500 mg daily later on that day. The next day, his oxygen saturation decreased, and worsening of the consolidation was noted on repeat chest radiograph. He also developed vivid visual hallucinations, became restless and agitated and disorientated to time, place and person. A diagnosis of varicella zoster infection complicated by varicella pneumonia and encephalitis was made. Valacyclovir was switched to intravenous acyclovir. A lumbar puncture showed increased protein and lymphocytes and was negative for cryptococcal antigen and neurotropic viruses. A magnetic resonance imaging scan of the brain showed no evidence of acute infarct, intracranial bleed, space-occupying lesion or hydrocephalus. The frequency of dialysis was increased with continuation of the renal adjusted dose of acyclovir.

Throughout the admission, his hemodialysis continued and he completed 2 weeks of IV acyclovir. His functional status improved back to the pre-morbid levels on discharge.

Discussion

The incidence of varicella in Singapore has been increasing since 1984 [1] and increased from 14,999 in 2003 to 24,031 in 2006. Mandatory notification of varicella ceased since 27th August 2007 [2]. Thus the latest reported figures are not known.

Primary infection with varicella is usually a benign and self-limiting illness in immunocompetent children. However, patients with end stage renal failure have lymphocytopenia and impaired lymphocyte function and are susceptible for disseminated varicella and its complications, with more severe morbidity and mortality rates [3, 4].

Our patient suffered severe complications of varicella infection that is pneumonia and viral encephalitis. Other known complications include myocarditis, corneal lesions, nephritis, arthritis, bleeding diatheses, acute glomerulonephritis, hepatitis and secondary bacterial superinfection of the skin.

The central nervous system is the most common extra cutaneous site of involvement, manifesting as acute cerebellar ataxia or diffuse encephalitis. These disorders typically develop toward the end of the first week of the exanthem, but can also precede the rash [5, 6]. Diffuse encephalitis most often occurs in adults and clinical manifestations include delirium, seizures, loss of consciousness and focal neurological signs including cranial nerve palsies, hemiparesis. Varicella encephalitis is more severe in immunosuppressed hosts who typically have a fulminant course with seizures, mental status changes and focal deficits including stroke syndromes. However very little data exist regarding the occurrence of varicella encephalitis in patients with end stage renal failure or those undergoing dialysis.

In the workup for VZV encephalitis, computed tomography or magnetic resonance imaging may or may not demonstrate abnormal radiographic findings, although electroencephalography is often abnormal in acute encephalitis. The cerebrospinal fluid contains lymphocytes and elevated levels of protein but normal glucose concentration, allowing differentiation from bacterial meningitis. Cerebrospinal fluid polymerase chain reaction (CSF PCR) can be used to detect VZV DNA, and has a specificity of greater than 95%, but the sensitivity is 30% or less in some studies [7]. Repeated mortality rates approach 10% and long-term neurologic sequelae are reported in up to 15% of survivors [810]. There is no proven effective therapy once encephalitis occurs, and supportive care remains the mainstay of management. Acyclovir has been used with anecdotal success [1113]. However, acyclovir neurotoxicity should always be considered in patients with prolonged or worsening neurological symptoms.

Varicella pneumonia is the most serious complication following varicella, develops more commonly in adults (up to 20% of cases) than in children, and accounts for the majority of morbidity and mortality seen in adults with varicella [11]. Risk factors linked to the development of varicella pneumonia include cigarette smoking, pregnancy and an immunosuppressed state [9]. Varicella pneumonia typically develops insidiously with symptoms of progressive dyspnea and dry cough. Patients demonstrate impaired gas exchange with progressive hypoxemia and are at high risk for respiratory failure and need for admission to intensive care for mechanical ventilation [14, 15]. Mortality rates approach 50% in patients with respiratory failure who require mechanical ventilation, despite institution of aggressive therapy and appropriate support measures [16, 17]. Chest radiographs typically reveal diffuse bilateral infiltrates. Prompt administration of intravenous acyclovir has been associated with clinical improvement and resolution of pneumonia in selected series [17, 18]. Resolution of pneumonitis parallels improvement of the skin rash, although fever and compromised pulmonary function may persist for weeks [11]. The use of steroids as adjunctive therapy for treatment of life-threatening varicella pneumonia is still controversial and should be further examined in rigorous controlled trials [19].

In immunosuppressed hosts such as ESRF patients or immunocompetent patients with disseminated disease such as pneumonia or encephalitis, varicella should be treated with IV acyclovir [20]. IV acyclovir reduces the occurrence of visceral complications but has no effect on healing of skin lesions or pain [11]. The recommended dose is 10 mg/kg Q8h for 7 days.

In December 2012, the FDA approved varicella zoster immune globulin (VariZIG) for administration to high risk individuals within 4 days of varicella exposure.

Acyclovir is an effective agent for the treatment of VZV infections but renal impairment results in high serum drug levels with resultant neurotoxicity. In renal failure, the half-life of acyclovir is increased from a maximum of 3.8 to 20 hours, and dosage reduction is required using the interval extension method [21]. Even the administration of recommended reduced doses can result in high serum levels and neurotoxicity, due to poor removal of acyclovir by peritoneal dialysis [4]. Tremors, disorientation, agitation, hallucinations, and delirium are common presentations of acyclovir-induced encephalopathy, whereas seizures, cerebellar ataxia, sensory symptoms, speech disorders, fever and cranial nerve palsies are much less frequent. Features distinguishing acyclovir neurotoxicity from VZV encephalitis include a temporal association between the symptoms and acyclovir use, as well as acellular CSF examination. However, acyclovir neurotoxicity should always be considered in patients with prolonged or worsening neurological symptoms for which daily hemodialysis is required often.

Studies show that many ESRF and kidney transplant patients do not have immunity to varicella [2225]. Primary varicella infection is common, up to 1.9% of renal transplant recipients are admitted in the first year post-transplant [26]. The infection can have serious complications and be lethal in these ESRF and renal transplant patients who are immunosuppressed [24, 2629].

Live attenuated varicella vaccine is generally contraindicated in immunosuppressed patients but has been proven to be safe when administered to both pediatric [23, 24, 29] and adult end stage renal failure patients on dialysis, [27] as well as renal transplant patients on immunosuppressive treatment [25].

Despite the general suppression of the immune system associated with uremia, patients with ESRF have high seroconversion rates to a two-dose varicella vaccination regimen. Seroconversion rates ranged from 87-100% [23, 2931] in ESRF pediatric patients waiting for transplant and 64% in adult ESRF patients [24]. 66.6% of pediatric renal transplant recipients seroconverted after a one–two dose varicella vaccination regimen [25]. Immunization guidelines in New Zealand recommend a two dose varicella vaccination regimen for children with deteriorating renal function, as early as possible before transplantation [32]. In the United States, the Centers for Disease Control and Prevention (CDC) adult immunization schedule recommend a two dose varicella vaccination regimen and a single dose zoster vaccination for patients with ESRF and recipients of hemodialysis [33, 34]. However, ESRF patients have an inability to maintain adequate antibody titers over time [35, 36]. Reports describe several patients in whom immunity to varicella waned in chronic renal insufficiency and in the post-transplant period [26, 27]. Hence there is a need for yearly surveillance of antibody titre as are done for Hepatitis B & C virus and cytomegalovirus. Special consideration for vaccination should also be given to persons who have close contact with or are at high risk of transmission to ESRF patients [32]. Although there are recommendations to administer varicella immunoglobulin to transplant patient coming in contact with varicella patients [37], the use of immunglobulins has risks and is expensive. Immunoglobulins should be reserved for those with imminent exposure to the virus. Varicella vaccination is a cheaper and more effective way for prevention of varicella.

Role of family physicians

There were 4,169 patients on dialysis in Singapore by 2008. This number represented a 89% increase since end 1998, when there were 2,209 patients on dialysis. The incidence of new ESRF patients requiring dialysis increases every year, from 564 new cases in 1998 to 1,212 cases in 2008. This represents a 115% increase during this 10-year period [3840]. In addition, patients are getting more elderly. In 2006, 52.1% and 5.1% of incident dialysis patients were over the age of 60 and 80 respectively. With a rapidly ageing population, Singapore can expect an increasing burden of end stage renal disease Family physicians should advise their ESRF patients of the life-threatening complications of varicella and urgent need for review if they develop fever or rash after coming in contact with varicella patients.

Currently, there are no local data on the seropositivity against varicella antibody in ESRF patients in Singapore or consensus guidelines for varicella vaccination. With an increasing burden of chronic kidney disease, Renal Physicians and Family Physicians in the Asia-Pacific region should meet and study the epidemiological data in each individual country and decide on consensus guidelines and how the varicella vaccination program can be targeted for those at risk. Research on the seroprevalence of varicella in ESRF patients should be conducted if such data is not currently available in Asia-Pacific countries.

Conclusions

Evidence supports the safety and efficacy of varicella vaccination in patients with end stage renal failure. Guidelines for varicella vaccination for ESRF patients are available in a few countries [33, 34]. The intent of our paper is to stimulate more research in the area of generating the need of consensus guidelines for universal vaccinations of ESRF patients on dialysis. Serious consequences of primary varicella infection can be avoided with appropriate vaccinations.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

ESRF: 

End stage renal failure

VZV: 

Varicella-Zoster virus.

Declarations

Acknowledgements

We would like to thank Associate Professor Lee Kheng Hock for his support.

Authors’ Affiliations

(1)
Department of Family Medicine and Continuing Care, Singapore General Hospital
(2)
Department of Renal medicine, Singapore General Hospital

References

  1. Ooi PL, Goh KT, Doraisingham S, Ling AE: Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 1992,23(1):22–25.PubMedGoogle Scholar
  2. Ernest WH, Imelda LE, Masitah I, Yeo CL: Knowledge, attitudes, and practices regarding chickenpox disease and its prevention in Singapore: comparison between parents and medical students. Proc Singapore Healthc 2012,21(4):257–264.View ArticleGoogle Scholar
  3. Heininger U, Seward JF: Varicella. Lancet 2006, 368: 1365. 10.1016/S0140-6736(06)69561-5View ArticlePubMedGoogle Scholar
  4. Kim CE, De Fijter CW: Herpes Zoster-associated encephalitis in a patient undergoing CAPD: Case report and literature review. Perit Dial Int 2007,27(4):391–394.Google Scholar
  5. Dangond F, Engle E, Yessayan L, Sawyer MH: Pre-eruptive varicella cerebellitis confirmed by PCR. Pediatr Neurol 1993,9(6):491–493. 10.1016/0887-8994(93)90032-8View ArticlePubMedGoogle Scholar
  6. Hausler M, Schaade L, Kemeny S, Schweizer K, Schoenmackers C, Ramaekers VT: Encephalitis related to primary varicella-zoster virus infection in immunocompetent children. J Neurol Sci 2002,195(2):111–116. 10.1016/S0022-510X(02)00017-5View ArticlePubMedGoogle Scholar
  7. David Beckham J, Tyler KL: Encephalitis. Mandell, Douglas, and Bennett’s Principles and practice of infectious disease 2010, 2: 1243–1264.View ArticleGoogle Scholar
  8. Preblud SR: Age specific risks of varicella complications. Pediatrics 1981,68(1):14–17.PubMedGoogle Scholar
  9. Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S: Life threatening complications of varicella. Am J Dis Child 1981,135(10):896–899.PubMedGoogle Scholar
  10. Fairley CK, Miller E: Varicella Zoster virus epidemiology – a changing scene? J Infect Dis 1996,174(3):314–319.View ArticleGoogle Scholar
  11. Longo , Fauci , Kasper , Hansen , Jameson : Varicella-Zoster virus infections. Harrison’s principles of internal medicine 2011, 18: 2426–2432.Google Scholar
  12. Poscher ME: Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDs: report of four cases and review. AIDS 1994,8(8):1115–1117.View ArticlePubMedGoogle Scholar
  13. Cinque P, Bossolasco S, Vago L, Fornara C, Lipari S, Racca S, Lazzarin A, Linde A: Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system in subclinical reactivation of VZV infection? Clin Infect Dis 1997,25(3):634–639. 10.1086/513754View ArticlePubMedGoogle Scholar
  14. Mohammed A: Varicella pneumonia in adults: 13 years’ experience with review of literature. Ann Thorac Med 2007,2(4):163–165. 10.4103/1817-1737.36551View ArticleGoogle Scholar
  15. Chiner E, Ballester I, Betlloch I, Blanquer J, Aguar MC, Blanquer R, Fernandez-Fabrellas E, Andreu AL, Briones M, Sanz F: Varicella-zoster virus pneumonia in an adult population: Has mortality decreased? Scand J Infect Dis 2010,42(3):215–221. 10.3109/00365540903428166View ArticlePubMedGoogle Scholar
  16. Feldman S: Varicella-zoster virus pneumonitis. Chest 1994,106(1):22S-27S.View ArticlePubMedGoogle Scholar
  17. Haake DA, Zakowski PC, Haake DL, Bryson YJ: Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990,12(5):788–798. 10.1093/clinids/12.5.788View ArticlePubMedGoogle Scholar
  18. Schlossberg D, Littman M: Varicella pneumonia. Arch Intern Med 1988,148(7):1630–1632. 10.1001/archinte.1988.00380070114027View ArticlePubMedGoogle Scholar
  19. Mer M, Richards GA: Corticosteroids in life-threatening varicella pneumonia. Chest 1998,114(2):426–431. 10.1378/chest.114.2.426View ArticlePubMedGoogle Scholar
  20. Drugs for non-HIV viral infections Treat Guidel Med Lett 2005,3(32):23–32.Google Scholar
  21. Bennett VM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I: Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983,3(3):155–193.View ArticlePubMedGoogle Scholar
  22. Genc G, Ozkaya O, Aygun C, Yakupoglu YK, Nalcacioglu H: Vaccination status of children considered for renal transplant: missed opportunities for vaccine preventable diseases. Exp Clin Transplant 2012,10(4):314–318. 10.6002/ect.2012.0059View ArticlePubMedGoogle Scholar
  23. Prelog M, Pohl M, Emisch B, Fuchshuber A, Huzly D, Jungraithmayr T, Forster J, Zimmerhackl LB: Demand for evaluation of vaccination antibody titers in children considered for renal transplantation. Pediatr Transplant 2007,11(1):73–76. 10.1111/j.1399-3046.2006.00602.xView ArticlePubMedGoogle Scholar
  24. Geel AL, Landman TS, Kal JA, Van Doomum GJ, Weimar W: Varicella Zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc 2006,38(10):3418–3419. 10.1016/j.transproceed.2006.10.090View ArticlePubMedGoogle Scholar
  25. Chaves Tdo S, Lopes MH, De Souza VA, Dos Santos SS, Pereira LM, Reis AD, David-Neto E: Seroprevalance of antibodies against Varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant 2005,9(2):192–196. 10.1111/j.1399-3046.2005.00279.xView ArticlePubMedGoogle Scholar
  26. Furth SL, Sullivan EK, Neu AM, Tejani A, Fivush BA: Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997,1(1):37–42.PubMedGoogle Scholar
  27. Verena W, Judith S, Meinrad B, Benedikt W, Stefan G, Girschick HJ, Johannes L, Schlegel PG, Matthias E: Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis. BMC Pediatr 2011, 11: 31. 10.1186/1471-2431-11-31View ArticleGoogle Scholar
  28. Fardrowski JJ, Furth SL: Varicella zoster virus: vaccination and implications in children with renal failure. Expert Rev Vaccines 2004,3(3):291–298. 10.1586/14760584.3.3.291View ArticleGoogle Scholar
  29. Nicholas JA W, Fitzpatrick MM, Highes DA, Brocklebank TJ, Judd BA, Lewis MA, Postlethwaite RJ, Smith PA, Gerald Corbitt on behalf of the Trans-pennine Paediatric Nephrology Study Group: Immunization against varicella in end stage & pre-end stage renal failure. Arch Dis Child 2000, 82: 141–143. 10.1136/adc.82.2.141View ArticleGoogle Scholar
  30. Geel A, Zuiderma W, Van Gelder T, Van Doorman G, Weimar W: Successful vaccination against varicella zoster virus prior to kidney transplantation. Transplant Proc 2005,37(2):952–953. 10.1016/j.transproceed.2004.11.023View ArticlePubMedGoogle Scholar
  31. Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA: Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2003,18(1):33–38. 10.1007/s00467-002-1006-zView ArticlePubMedGoogle Scholar
  32. Ministry of Health: Immunisation Handbook 2011. Wellington: Ministry of Health; 2011. http://www.moh.govt.nzGoogle Scholar
  33. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention: Recommended Adult Immunization Schedule – United States 2013. 2013.Google Scholar
  34. Soni R, Horowitz B, Unruh M: Immunization in end stage renal disease: opportunity to improve outcomes. Semin Dial 2013,26(4):416–426. 10.1111/sdi.12101View ArticlePubMedGoogle Scholar
  35. Rodby RA, Trenholme GM: Vaccination of the dialysis patient. Semin Dial 1991,4(2):102–105.View ArticleGoogle Scholar
  36. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK: The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005,46(6):997–1011. 10.1053/j.ajkd.2005.08.032View ArticlePubMedGoogle Scholar
  37. Barril G, Teruel JL: Vaccination scheme in advanced chronic kidney disease. Nefrol 2008,28(Suppl 3):95–99.Google Scholar
  38. Ministry of Health: Kidney Dialysis. MOH Information Papers. Statistics, Publications and Resources. Singapore: Ministry of Health; 2006.Google Scholar
  39. Vathsala A: Twenty-five facts about kidney disease in Singapore: in remembrance of world kidney day. Ann Acad Med 2007,36(3):157–160.Google Scholar
  40. Choong HL: Seventh report of the Singapore Renal Registry 2007/2008. 2008.Google Scholar

Copyright

© Low et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Advertisement